Clinical trials
Observational Glycogen Storage Disease Type II trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 7 |
| Unknown status | 4 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Duke University | 7 |
| Genzyme, a Sanofi Company | 6 |
| O & O Alpan LLC | 3 |
| University of Florida | 3 |
| Amicus Therapeutics | 2 |
| Sanofi | 2 |
| Lysosomal and Rare Disorders Research and Treatment Center, Inc. | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
| RTI International | 1 |
| Serhat Gumrukcu, MD PhD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glycogen Storage Disease Type II | 29 |
| Gaucher Disease | 4 |
| Fabry Disease | 3 |
| Lysosomal Storage Diseases | 3 |
| Anemia, Sickle Cell | 2 |
| Cystic Fibrosis | 2 |
| Muscular Diseases | 2 |
| Muscular Dystrophy, Duchenne | 2 |
| Niemann-Pick Diseases | 2 |
| beta-Thalassemia | 2 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.